MannKind

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

CEO

Michael E. Castagna

CEOMichael E. Castagna

Employees

592

Employees592

Headquarters

Danbury, Connecticut

HeadquartersDanbury, Connecticut

Founded

1991

Founded1991

Employees

592

Employees592

MNKD Key Statistics

Market cap

1.25B

Market cap1.25B

Price-Earnings ratio

-16.26

Price-Earnings ratio-16.26

Dividend yield

—

Dividend yield—

Average volume

3.43M

Average volume3.43M

High today

$4.09

High today$4.09

Low today

$3.63

Low today$3.63

Open price

$3.92

Open price$3.92

Volume

4.99M

Volume4.99M

52 Week high

$6.51

52 Week high$6.51

52 Week low

$2.23

52 Week low$2.23

Stock Snapshot

As of today, MannKind(MNKD) shares are valued at $3.93. The company's market cap stands at 1.25B, with a P/E ratio of -16.26.

On 2026-11-08, MannKind(MNKD) stock traded between a low of $3.63 and a high of $4.09. Shares are currently priced at $3.93, which is +8.2% above the low and -4.1% below the high.

MannKind(MNKD) shares are trading with a volume of 4.99M, against a daily average of 3.43M.

During the past year, MannKind(MNKD) stock moved between $2.23 at its lowest and $6.51 at its peak.

MNKD News

Investing.com 2d

Cantor Fitzgerald raises MannKind stock price target to $10 on Tyvaso momentum - Investing.com

...

Zacks 2d

MannKind Reports Q3 Loss, Misses Revenue Estimates

MannKind (MNKD Quick QuoteMNKD - Free Report) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. Th...

Simply Wall St 5d

Learn Why The Bull Case For MannKind Stock Could Change Following Product Approvals

MannKind has had a difficult 2026, with attention turning to whether the current valuation aligns with its cash flow potential as revenue reflects contributions...

Analyst ratings

89%

of 9 ratings

Buy

88.9%

Hold

11.1%

Sell

More MNKD News

Simply Wall St 6d

MannKind Adds Furoscix And New Approvals, Is The Growth Potential Fully Priced In?

Advertisement Event driven interest in MannKind Fresh attention on MannKind (MNKD) follows recent analysis of its Furoscix ReadyFlow acquisition and new produ...

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.